Re-Registration of Medical Devices in Malaysia: Five-Year Validity and Renewal

1. Key takeaways

A Malaysian medical device registration is valid for five years. The rule is stated in section 1.3 of MDA/GL/08, the Guideline for Re-Registration of Registered Medical Device, third edition, June 2023. Once the five-year period expires, the device may no longer be imported, exported or placed on the market unless a re-registration application has been made and approved. Re-registration is therefore not an administrative extension of an existing record; it is a fresh regulatory decision that happens to preserve the existing registration number and product identity. Planning it as a project with its own evidence requirements, rather than as a renewal formality, is the difference between continuous market access and an avoidable gap.

• The registration is valid for five years, after which re-registration is required to continue import, export or supply.
• MeDC@St opens the re-registration function one year before the expiry date.
• Where an open change notification exists, the re-registration function is accessed under the completed change notification application.
• Class B, Class C and Class D require CAB re-assessment against the four elements of QMS, PMS, TD and DoC.
• The CAB also reviews change notifications that MDA has already approved as part of the re-assessment.
• Class A is not subject to the CAB assessment step in the renewal process.
• Unapproved changes cannot be introduced through the renewal application; they must go through a change notification first.

2. Legal basis

The re-registration framework is set out in MDA/GL/08, with section 1.3 establishing the five-year validity and the obligation to re-register before expiry, and sections 4 and 5 describing the assessment and application handling. The four-element re-assessment for Class B, Class C and Class D derives from the Third Schedule to the Medical Device Regulations 2012, which is the same structure applied at first registration. Change control is governed by MDA/GD/0020, the change notification guidance, and the interaction between change notifications and renewal is one of the points clarified in the MDA MedCast announcement FAQ dated 10 July 2026, Revision 2, at question 3. Fees follow the Fifth Schedule as amended by P.U.(A) 330/2025: from 2026, Class A is RM500 plus RM750; Class B is RM250 plus RM1,000; Class C is RM500 plus RM2,000; Class D is RM750 plus RM3,000; and devices incorporating a medicinal substance carry a registration fee of RM5,000. Re-registration is charged on the same basis as first registration.

3. Expert insights

The most consequential feature of the Malaysian renewal model is that Class B, Class C and Class D devices are re-assessed rather than merely re-recorded. The CAB repeats the four-element assessment, and it also reviews the change notifications that MDA has already approved. That second function is easy to underestimate. It means the history of changes made during the five-year period becomes part of the renewal evidence, and any change that was implemented without a corresponding approval will surface at this point. Manufacturers who treat change control as a separate administrative stream, disconnected from the registration file, discover the connection during renewal, when the options for remediation are narrowest.

The rule that unapproved changes cannot be modified through the renewal application follows from the same logic, and it is reinforced by the prohibition on submitting renewal and change notification simultaneously. The sequence is therefore fixed: obtain approval for the change, then renew on the basis of the approved state. Projects that attempt to combine the two, on the assumption that a renewal is a convenient moment to tidy up the file, find that the system will not accept the combination and that the change must be processed separately first, which typically pushes the renewal past the expiry date.

Timing is the third variable, and it is fully within the applicant’s control. The system opens the function one year before expiry, which sets the outer boundary, but MDA recommends submitting well before that boundary, usually at least three to six months ahead, to leave buffer for system and documentation issues. A practical approach works backwards from expiry: begin CAB communication in year four, complete the technical documentation update by the three-and-a-half-year point, and hold the remaining period for review and response. The calendar, not the review, is what most often determines whether the renewal completes on time.

4. Practical recommendations

• Maintain a registration expiry calendar covering every certificate, with the renewal window calculated from the expiry date rather than from the anniversary of approval.
• Start CAB communication in year four and complete the technical documentation update by the three-and-a-half-year point, working backwards from expiry.
• Submit at least three to six months before expiry, in line with MDA advice, so that system and documentation issues do not consume the remaining margin.
• Clear all open change notifications before the renewal window opens, since renewal and change notification cannot be submitted at the same time.
• Reconcile the approved change history against the current device state, treating any implemented but unapproved change as a defect to be resolved first.
• Budget the renewal at the same fee level as first registration, using the current Fifth Schedule figures for the applicable class.
• Confirm with the CAB what evidence it will expect for the four elements at re-assessment, and prepare the PMS record over the full validity period rather than the most recent year.

5. Verification checklist

• □ MDA/GL/08, Guideline for Re-Registration of Registered Medical Device, June 2023, third edition, sections 1.3, 4 and 5 have been reviewed.
• □ The MDA MedCast announcement FAQ of 10 July 2026, Revision 2, question 3 has been checked for the change notification interaction.
• □ Fees reflect the Fifth Schedule as amended by P.U.(A) 330/2025 for the applicable class, including the RM5,000 registration fee for devices incorporating a medicinal substance.
• □ MDA/GD/0020 has been reviewed for the change notification route applicable to any pending modification.
• □ No change notification is open at the point of renewal submission, and no renewal is filed simultaneously with a change notification.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Malaysia. Our team prepares dossiers to ASEAN CSDT structure, manages submissions and deficiency responses with the MDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com